Utilization of health care and the costs for patients with rheumatoid arthritis treated with TNF-α inhibitors in the Czech Republic
Authors:
L. Šedová 1; J. Skoupá 2; V. Černá 2
Authors‘ workplace:
Revmatologický ústav Praha, 2Pharma Projects s. r. o.
1
Published in:
Čes. Revmatol., 17, 2009, No. 2, p. 74-77.
Category:
Original Papers
Overview
According to international publications, the annual costs of a patient with rheumatoid arthritis represent c. 10.000 USD, with dominance of indirect costs. This study is one of the first studies that deals with the cost analysis of rheumatoid arthritis in the Czech Republic. The analysis of health care utilization throughout the last year was performed on the group of 113 patients who met the criteria for biological therapy, and the rates between direct and indirect costs were compared. In a number of indicators, this study acknowledges the results obtained in other countries on decreased utilization of health care by patients treated with TNF-α inhibitors.
Key words:
rheumatoid arthritis, biological therapy, cost efficacy, direct and indirect costs
Sources
1. Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007; 19: 272–276.
2. Kavenaugh A, Cohen S, Cush JJ. The evolving use of tumour necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol 2004; 31(10): 1881–4.
3. Lyseng-Williamson KA, Ploskem GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22 (16): 1071–95.
4. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis: technology appraisal guidance. London: National Institute for Clinical Excellence, 2002: 36.
5. Vencovský J, Tegzová D, Krofta K, Pavelka K. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF – doplněk standardních léčebných postupů u revmatoidní artritidy. Čes Revmatol 2004; 12(1): 20–29.
6. Péntek M, Kobelt G, Czirják L. Cost of RA in Hungary. J Rheumatol 2007; 34(6): 1437–39.
7. Guillemin F, Durieux S, Daurés JP, et al. Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004; 31: 1297–304.
8. Verstappen SM, Verkleij H, Bijlsma JW, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004; 63: 817–24.
9. Westhovens R, Boonen A, Verbruggen L, et al. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 2005; 24: 615–9.
10. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept and infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4–10.
11. Armstrong DJ, et al. The impact of anti-TNF-therapy on the nature of service provision. Rheumatology 2006; 45: 112–123.
12. Májer I, Brodszky V, Gulácsi L. Az egészég-gazdaságtani modellezés szerepe a gyógyszer-finanszírozásban. Farmakoökonómia 2007; 5: 34–38.
13. Kobelt G, Lindgren P, et al. Modeling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005; 44: 1169–1175.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2009 Issue 2
Most read in this issue
- HLA-Cw*0602 is a predisposing allele to develop psoriatic arthritis
- Limited significance of procalcitonin in differentiation between sepsis and flare of a rheumatic disease
- Secondary immunodeficiency with infectious complications following immunosuppressive therapy in a female patient with systemic lupus erythematosus
- Utilization of health care and the costs for patients with rheumatoid arthritis treated with TNF-α inhibitors in the Czech Republic